Synendos Therapeutics Expands Series A to CHF 24 million with new investment
Synendos Therapeutics is thrilled to announce an extension to the Series A financing with the addition of Ysios Capital to its syndicate of European investors. Ysios Capital’s contribution brings the total raised to CHF 24 million, following a Series A financing co-led by Kurma Partners and Sunstone Life Science Ventures announced in November 2020.
In addition, Synendos Therapeutics is delighted to announce securing a prestigious Eurostars grant (EU funding scheme) to expand proof-of-concept preclinical studies for PTSD and the appointment of Professor Jutta Heim as Chair to the Board.
Press inquiries should be adressed to: